| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_991ad1ca825e5b12bbabcacaa6192caf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17a1e8c3ec7e96b9e113b32de3730cc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e3fd4931af5676a7294d197937fcdd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ebfc8d66ac1303ed1e3e999d65aa236
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94d7209cce2db3c43022b2f3baa55584 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4743 |
| filingDate |
2003-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ca27d67cee9eeef6888ccf4d67b229c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52c5c5db807f399ab299b198cb1ad914
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d49695f3a7a432a68749511d4f57b6a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7f7b79d036112c2a5ef25a76322ad6f |
| publicationDate |
2004-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004028470-A2 |
| titleOfInvention |
Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| abstract |
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2979824-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010513570-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11076593-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007071670-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7906666-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3116493-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10070643-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9084801-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014028830-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007059431-A1 |
| priorityDate |
2002-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |